Plus Therapeutics(PSTV) - 2024 Q2 - Quarterly Results

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium ( 186Re) Obisbemeda for Leptomeningeal Metastases Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trial Management to host conference call August 14, 2024 at 5:00 p.m. ET AUSTIN, Texas, August 14, 2024 (GLOBE NEWSWIRE) – Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compan ...